Clinical Trial Update: Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating ibritinib in combination with pomalidomide and dexamethasone for relapsed/refractory multiple myeloma; study terminated with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Ibrutinib (ibrutinib)
• Pomalidomide (Pomalidomide)

Snippet

Sponsor: Pharmacyclics LLC. | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-04-23